Listing code
113.05
Children (Part B)
Body system
113.00
Cancer (malignant neoplastic diseases, children)
Subsections
4
Lettered criteria paths
Step in evaluation
3 of 5
Listing match approves the claim
SSA listing text and criteria
Lymphoma (excluding all types of lymphoblastic lymphoma-- 113.06 ) (See 113.00K1 )
Subsection A
Non-Hodgkin lymphoma (including Burkitt's and anaplastic large cell), with either 1 or 2: 1. Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis. Consider under a disability for 24 months from the date of diagnosis. Thereafter, evaluate under 113.05A2 , or any residual impairment(s) under the criteria for the affected body system. 2. Persistent or recurrent following initial anticancer therapy. OR
- Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis. Consider under a disability for 24 months from the date of diagnosis. Thereafter, evaluate under 113.05A2 , or any residual impairment(s) under the criteria for the affected body system.
- Persistent or recurrent following initial anticancer therapy. OR
Subsection B
Hodgkin lymphoma, with either 1 or 2: 1. Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis. Consider under a disability for 24 months from the date of diagnosis. Thereafter, evaluate under 113.05B2 , or any residual impairment(s) under the criteria for the affected body system. 2. Persistent or recurrent following initial anticancer therapy. OR
- Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis. Consider under a disability for 24 months from the date of diagnosis. Thereafter, evaluate under 113.05B2 , or any residual impairment(s) under the criteria for the affected body system.
- Persistent or recurrent following initial anticancer therapy. OR
Subsection C
With bone marrow or stem cell transplantation. Consider under a disability until at least 12 months from the date of transplantation. Thereafter, evaluate any residual impairment(s) under the criteria of the affected body system. OR
Subsection D
Mantle cell lymphoma.
Source: SSA Blue Book listing 113.05. Last synced 2026-05-04.
Where claims under 113.05 usually fail
One pitfall is mixing up the exclusion for lymphoblastic lymphoma: if the lymphoma is lymphoblastic, it falls under 113.06 instead of 113.05. Another pitfall is treating any imaging result as sufficient, even when the record does not show the required site involvement (bone marrow, brain, spinal cord, liver, or lung) at initial diagnosis, or persistent or recurrent disease after anticancer therapy. A third pitfall is missing the difference between initial diagnosis versus after therapy, since 113.05A and 113.05B each require either initial site involvement or the persistence/recurrence after treatment. A fourth pitfall is overlooking 113.05C (bone marrow or stem cell transplantation) as its own pathway, or overlooking 113.05D (mantle cell lymphoma) when the diagnosis matches those exact criteria.
Medical evidence that strengthens this claim
Strong evidence for 113.05 requires medical records that specify the lymphoma type and the extent and site of involvement, especially whether bone marrow, brain, spinal cord, liver, or lung are involved at initial diagnosis. For procedures like biopsy or needle aspiration, the record typically needs both an operative note and a pathology report, because both are generally required for operative procedures. When operative documents cannot be obtained, summaries of hospitalization(s) or other medical reports may be accepted, but they should include the findings at surgery and, when appropriate, the pathological findings. Depending on the pathway chosen, documentation should also address whether the lymphoma was persistent or recurrent after initial anticancer therapy (113.05A or 113.05B), whether bone marrow or stem cell transplantation occurred (113.05C), or whether the lymphoma type is mantle cell lymphoma (113.05D).
What happens if your records do not meet this listing
Even if the exact 113.05A/B/C/D criteria are not met, the decision process moves to later steps that consider other impairments and effects. For 113.05A and 113.05B, the criteria also describe a timeline approach: there is a period considered as a disability for 24 months from the date of diagnosis when the criteria are met, then later evaluation under 113.05A2 or 113.05B2 (or evaluation of residual impairment(s) under the criteria for the affected body system). That means many cases that do not qualify under the strict early criteria can still be evaluated later based on residual effects or other qualifying impairments.
Work activity and the SGA gate for this condition
For children in Part B under listing 113.05, the medical criteria focus on site involvement (bone marrow, brain, spinal cord, liver, or lung) at initial diagnosis for non-Hodgkin lymphoma (113.05A) or Hodgkin lymphoma (113.05B), or persistence or recurrence after initial anticancer therapy, or lymphoma with bone marrow or stem cell transplantation (113.05C), or mantle cell lymphoma (113.05D). When 113.05A or 113.05B criteria are met, the criteria include a disability consideration period for 24 months from the date of diagnosis, and then later evaluation under 113.05A2 or 113.05B2 or residual impairment(s). For 113.05C, the criteria describe disability consideration until at least 12 months from the date of transplantation, and then later evaluation of residual impairment(s) under the affected body system.
Listing 113.05 FAQ
Questions that come up repeatedly for lymphoma (excluding all types of lymphoblastic lymphoma-- 113.06 ) disability claims.